---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 10, 2008 at 8:23 AM
Subject: 09.06.2008 - DJ HUGIN NEWS/Epigenomics Successfully Completes Clinical Study in Lung Cancer Diagnosis (4investors)
To: mesothelioma77@gmail.com
Berlin, Germany, and Seattle, WA, USA, June 9, 2008 - Epigenomics AG (Frankfurt Prime Standard: ECX), a molecular diagnostics company focusing on the development and commercialization of products for cancer based on DNA methylation, today announced that it successfully completed a clinical study in its lung cancer program.
Mon, 09 Jun 2008 07:01:41 GMT
___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12aue1l27/*http%3A//www.4investors.de/php_fe/indexdow.php?sektion=dowjones&ID=67060
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 10, 2008 at 8:23 AM
Subject: 09.06.2008 - DJ HUGIN NEWS/Epigenomics Successfully Completes Clinical Study in Lung Cancer Diagnosis (4investors)
To: mesothelioma77@gmail.com
Berlin, Germany, and Seattle, WA, USA, June 9, 2008 - Epigenomics AG (Frankfurt Prime Standard: ECX), a molecular diagnostics company focusing on the development and commercialization of products for cancer based on DNA methylation, today announced that it successfully completed a clinical study in its lung cancer program.
Mon, 09 Jun 2008 07:01:41 GMT
___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12aue1l27/*http%3A//www.4investors.de/php_fe/indexdow.php?sektion=dowjones&ID=67060
--
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc